[1]贾立永.冰硼散加减外用联合穴位注射治疗原发性肝癌中重度疼痛的临床疗效[J].医学信息,2022,35(06):171-173.[doi:10.3969/j.issn.1006-1959.2022.06.045]
　JIA Li-yong.Clinical Effect of Modified Bingpeng Powder Combined with Acupoint Injection in the Treatment of Moderate and Severe Pain in Primary Hepatic Carcinoma[J].Medical Information,2022,35(06):171-173.[doi:10.3969/j.issn.1006-1959.2022.06.045]
点击复制

冰硼散加减外用联合穴位注射治疗原发性肝癌中重度疼痛的临床疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年06期
页码:
171-173
栏目:
中医中药
出版日期:
2022-03-15

文章信息/Info

Title:
Clinical Effect of Modified Bingpeng Powder Combined with Acupoint Injection in the Treatment of Moderate and Severe Pain in Primary Hepatic Carcinoma
文章编号:
1006-1959（2022）06-0171-03
作者:
贾立永
（建昌县人民医院普外科，辽宁 建昌 125300）
Author(s):
JIA Li-yong
(Department of General Surgery,Jianchang County People’s Hospital,Jianchang 125300,Liaoning,China)
关键词:
原发性肝癌; 冰硼散; 穴位注射; 癌性疼痛; 睡眠质量
Keywords:
Primary hepatic carcinoma; Bingpeng powder; Acupoint injection; Cancer pain; Sleep quality
分类号:
R735.7
DOI:
10.3969/j.issn.1006-1959.2022.06.045
文献标志码:
A
摘要:
目的 观察冰硼散加减外用联合穴位注射治疗原发性肝癌（PHC）中重度疼痛的临床疗效。方法 选取2019年5月-2021年5月建昌县人民医院收治的68例PHC中重度疼痛患者，按照随机数字表法分为对照组和观察组，各34例。对照组给予盐酸羟考酮缓释片治疗，观察组在其基础上应用冰硼散加减外用联合穴位注射治疗，比较两组镇痛效果、疼痛程度数字评估量表（NRS）评分、匹兹堡睡眠质量指数（PSQI）评分、前列腺素E2（PGE2）、缓激肽（BK）、β-内啡肽（β-ENP）及不良反应。结果 观察组镇痛有效率为91.18%，高于对照组的70.59%（P＜0.05）；两组NRS、PSQI评分低于治疗前，且观察组低于对照组（P＜0.05）；两组PGE2、BK低于治疗前，β-ENP高于治疗前，且观察组PGE2、BK低于对照组，β-ENP高于对照组（P＜0.05）；观察组不良反应发生率为29.41%，低于对照组的52.94%（P＜0.05）。结论 冰硼散加减外用联合穴位注射治疗PHC中重度疼痛效果确切，可有效减轻其癌性疼痛，改善睡眠质量，降低肿瘤细胞炎性因子分泌，减少药物不良反应。
Abstract:
Objective To observe the clinical efficacy of modified Bingpeng powder combined with acupoint injection in the treatment of moderate to severe pain in primary hepatic carcinoma (PHC).Methods A total of 68 patients with moderate to severe pain of PHC admitted to Jianchang County People’s Hospital from May 2019 to May 2021 were selected and randomly divided into control group and observation group, with 34 cases in each group. The control group was treated with oxycodone hydrochloride sustained release tablets, and the observation group was treated with Bingpeng powder combined with acupoint injection. The analgesic effect, NRS score, Pittsburgh sleep quality index (PSQI) score, prostaglandin E2 (PGE2), bradykinin (BK), β-endorphin (β-ENP) and adverse reactions were compared between the two groups.Results The effective rate of analgesia in the observation group was 91.18%, which was higher than 70.59% in the control group(P<0.05). The NRS and PSQI scores of the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05). PGE2 and BK in the two groups were lower than those before treatment, and β-ENP was higher than that before treatment, PGE2 and BK in the observation group were lower than those in the control group, and β-ENP was higher than that in the control group(P<0.05). The incidence of adverse reactions in the observation group was 29.41%, which was lower than 52.94% in the control group(P<0.05).Conclusion Modified Bingpeng powder combined with acupoint injection is effective in the treatment of moderate and severe pain in PHC, which can effectively relieve cancer pain, improve sleep quality, reduce the secretion of inflammatory factors in tumor cells and reduce adverse drug reactions.

参考文献/References:

[1]胡陵静,郭婷婷,叶海英,等.中医外治四联梯级疗法治疗癌性疼痛的探讨与应用[J].中国中医急症,2021,30(1):105-108.[2]Swarm RA,Paice JA,Anghelescu DL,et al.Adult Cancer Pain,Version 3.2019, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2019,17(8):977-1007.[3]欧喜荣,柯龙珠,罗莉.观察癌痛规范化治疗联合中医外治缓解癌性疼痛的临床疗效[J].中西医结合心血管病电子杂志,2020,8(23):155.[4]周燕,胡陵静,郭婷婷,等.中医外治三联疗法综合治疗重度癌性疼痛的临床观察[J].中医临床研究,2019,11(18):90-93.[5]王静,宋娜,徐宏建,等.癌痛规范化治疗联合中医外治缓解癌性疼痛临床观察[J].实用中医药杂志,2019,35(9):1075-1076.[6]骆嘉华,刘振海,李增辉.吗啡足三里穴位注射治疗重度癌痛的临床疗效研究[J].陕西中医,2018,39(2):253-255.[7]中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中国实用外科杂志,2020,40(2):121-138.[8]贾立群,娄彦妮.癌性疼痛中医外治诊疗规范专家共识意见[J].北京中医药,2014,33(4):305-307.[9]李萍,丁慧,张恩欣.针刺结合麦粒灸联合三阶梯止痛法治疗中重度癌性疼痛效果观察[J].山东医药,2017,57(18):43-45.[10]王林.莲莪止痛方联合针灸治疗晚期肝癌癌痛26例[J].深圳中西医结合杂志,2018,28(16):56-57.[11]高建清,雷艳容,陈红蓓.中药外敷结合针刺治疗对肺癌患者癌性疼痛及中医证候积分影响研究[J].四川中医,2019,37(4):93-96.[12]吴继,王瑶,张琰,等.针灸联合耳穴疗法配合三阶梯止痛药对癌性疼痛影响的临床观察[J].上海中医药杂志,2017,51(10):48-51.[13]沈丽贤,王宝岩,张亚芹,等.止痛散外敷、针刺和复方丹参注射液穴位注射辅治晚期肝癌癌痛的临床观察[J].疑难病杂志,2015,14(4):409-412.[14]韩鹏炳,李瑾,冀雪娟,等.加味冰硼散漱口液对放射性口腔黏膜炎炎性介质及预后的影响分析[J].中华中医药学刊,2019,37(6):1522-1525.[15]王兆君,高力英.加味冰硼散漱口液含漱对头颈癌放疗患者免疫功能的影响[J].中国医药导报,2020,17(26):91-94.[16]任静,王淑美.穴位注射在肿瘤辅助治疗中的作用[J].中医肿瘤学杂志,2019,1(2):49-53.[17]沈丽贤,王明波,张红宇,等.穴位注射对肝癌癌痛患者镇痛效果影响的研究[J].河北中医药学报,2014,29(4):35-37.[18]吴昭利,祝云鹤,李成军,等.冰硼散加减外用联合穴位注射治疗原发性肝癌中重度疼痛[J].中医学报,2019,34(10):2249-2253.[19]Zhang WQ,Xiao ZL,Wu ZL,et al.Systematic review of external applications combined with three-step analgesic therapy in treating primary liver cancer pain[J].China Journal of Chinese Materia Medical,2019,44(9):1938-1945.[20]赖如京,涂芸芸,邱火秀.羟考酮缓释片联合度洛西汀治疗晚期癌性疼痛的疗效及对患者外周血β-内啡肽水平的影响[J].黑龙江医药,2016,29(6):1148-1150.

相似文献/References:

[1]张 黎.中晚期原发性肝癌介入治疗的临床效果及对 肝功能的影响[J].医学信息,2018,31(09):20.[doi:10.3969/j.issn.1006-1959.2018.09.006]
　ZHANG Li.The Clinical Effect of Interventional Treatment of Primary Liver Cancer in Middle and Late Stage and its Effect on Liver Function[J].Medical Information,2018,31(06):20.[doi:10.3969/j.issn.1006-1959.2018.09.006]
[2]朱 瑞.血清AFP、CA19-9、CEA单项及三者联合检验对原发性肝癌早期诊断与治疗的意义对比[J].医学信息,2018,31(13):154.[doi:10.3969/j.issn.1006-1959.2018.13.047]
　ZHU Rui.Comparison of the Significance of Serum AFP,CA19-9,CEA Single and Combined the Three Methods Tests in the Early Diagnosis and Treatment of Primary Liver Cancer[J].Medical Information,2018,31(06):154.[doi:10.3969/j.issn.1006-1959.2018.13.047]
[3]侯宝松,王海峰,徐海晶,等.大黄蛰虫方合逍遥方加减对原发性肝细胞癌 TACE术后综合征影响[J].医学信息,2018,31(14):53.[doi:10.3969/j.issn.1006-1959.2018.14.017]
　HOU Bao-song,WANG Hai-feng,XU Hai-jing,et al.Effect of Rhubarb Aphid Fanghe Xiaoyaofang Decoction on Postoperative TACE Syndrome of Primary Hepatocellular Carcinoma[J].Medical Information,2018,31(06):53.[doi:10.3969/j.issn.1006-1959.2018.14.017]
[4]郑德仁.多排螺旋CT诊断肝血管瘤及肝脏肿瘤的临床价值分析[J].医学信息,2018,31(20):160.[doi:10.3969/j.issn.1006-1959.2018.20.050]
　ZHENG De-ren.Clinical Value of Multi-slice Spiral CT in Diagnosis of Hepatic Hemangioma and Liver Tumor[J].Medical Information,2018,31(06):160.[doi:10.3969/j.issn.1006-1959.2018.20.050]
[5]赵鱼扉,史政荣.肝脏储备功能临床应用研究[J].医学信息,2019,32(10):35.[doi:10.3969/j.issn.1006-1959.2019.10.013]
　ZHAO Yu-fei,SHI Zheng-rong.Clinical Application of Liver Reserve Function[J].Medical Information,2019,32(06):35.[doi:10.3969/j.issn.1006-1959.2019.10.013]
[6]姜天奇,张洪亮.原发性肝癌的中西医治疗现状[J].医学信息,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
　JIANG Tian-qi,ZHANG Hong-liang.Current Status of Treatment of Primary Liver Cancer with Traditional Chinese Medicine and Western Medicine[J].Medical Information,2019,32(06):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
[7]邢时龙,淦 勤.原发性肝癌患者血清25-羟基维生素D3水平与免疫抑制因子IL-10的关系[J].医学信息,2020,33(01):101.[doi:10.3969/j.issn.1006-1959.2020.01.030]
　XING Shi-long,GAN Qin.Relationship Between Serum 25-hydroxyvitamin D3 Level and Immunosuppressive Factor IL-10 in Patients with Primary Liver Cancer[J].Medical Information,2020,33(06):101.[doi:10.3969/j.issn.1006-1959.2020.01.030]
[8]王瑞航,姚升娟,张 晨,等.肝动脉化疗栓塞介入术对原发性肝癌患者近期疗效及Child-Pugh分级的影响[J].医学信息,2020,33(17):101.[doi:10.3969/j.issn.1006-1959.2020.17.029]
　WANG Rui-hang,YAO Sheng-juan,ZHANG Chen,et al.Effect of Interventional Hepatic Artery Chemoembolization on the Short-term Efficacy and Child-Pugh Classification of Patients with Primary Liver Cancer[J].Medical Information,2020,33(06):101.[doi:10.3969/j.issn.1006-1959.2020.17.029]
[9]郑澹宁,孙国平.肝动脉化疗栓塞的肝癌患者生活质量调查研究[J].医学信息,2020,33(22):127.[doi:10.3969/j.issn.1006-1959.2020.22.036]
　ZHENG Dan-ning,SUN Guo-ping.Survey on the Quality of Life of Hepatocellular Cancer Patients Undergoing Transcatheter Arterial Chemoembolization[J].Medical Information,2020,33(06):127.[doi:10.3969/j.issn.1006-1959.2020.22.036]
[10]包学智.经肝动脉化疗栓塞联合射频消融术治疗中晚期原发性肝癌的效果[J].医学信息,2020,33(19):110.[doi:10.3969/j.issn.1006-1959.2020.19.033]
　BAO Xue-zhi.The Effect of Transhepatic Artery Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Advanced Primary Liver Cancer[J].Medical Information,2020,33(06):110.[doi:10.3969/j.issn.1006-1959.2020.19.033]

更新日期/Last Update: 1900-01-01